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the cost-effectiveness in Canada of the treatments recommended
by the Infectious Diseases Society of America guidelines for mild
diabetic foot infections. METHODS: A decision-tree model was
developed using TreeAge Pro-2007 and clinical experts. Success
probabilities were derived from published randomized controlled
trials. Drug costs were obtained from the 2007 Ontario Drug
Beneﬁt Formulary and McKesson Inc., and amputation costs
from CMG’s 2002/2003 database, with values adjusted to 2007
using the Canadian Consumer Price Index. Hospitalization costs
were obtained from Sunnybrook Hospital’s 2003/3004 database,
adjusted to 2007. One-way and two-way sensitivity analyses
were performed to test the robustness of the decision tree model
by varying the clinical success rates and costs of antibiotics.
Probabilistic sensitivity analyses were also performed using
Monte Carlo simulations. RESULTS: Clindamycin was cost-
effective, dominating all other choices, and cephalexin had
the next best proﬁle. Expected success rates were 99.4% for
clindamycin, 97.8% for cephalexin, 95.4% for amoxicillin-
clavulanate, 95.2% for cloxacillin and 95.0% for levoﬂoxacin.
The expected cost of clindamycin ($361.33) was substantially
lower than the next best alternative, cephalexin ($1239.99); a
cost difference of $878.66 per patient treated. However, success
rates were based on a single small trial for each drug (n < 30 for
each). In sensitivity analyses, the model/decision was sensitive to
changes in efﬁcacy rates and costs within plausible ranges for
clindamycin and cephalexin. CONCLUSION: Clindamycin was
cost-effective in treating mild diabetic foot infection but our
model had several limitations/assumptions; therefore, the results
should be interpreted cautiously. In general, few clinical studies
have evaluated oral antibiotics for treating these infections and
more are needed.
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OBJECTIVE: Invasive candidiasis has become a frequent and a
high economic impact disease in Mexican hospitals. The purpose
of this study was to develop an economic assessment to evaluate
the cost-effectiveness between different antifungal agents for the
treatment of non neutropenic patients with invasive candidiasis
at the Social Security Mexican Institute (IMSS) from the payer’s
perspective. METHODS: A 12-week Bayesian decision-tree
model was performed to simulate costs and effectiveness out-
comes. Effectiveness measures were the rate of clinical success
without adverse events (AE) and the patient’s stay length in
intensive care units (ICU) at the end of the follow-up period.
Effectiveness data and transition probabilities were taken from
international published literature. The comparators were anidu-
lafungin (100 mg/day); liposomal amphotericin B (3 mg/kg/day);
amphotericin B (0.6 mg/kg/day); ﬂuconazol (200 mg/day);
caspofungin (initial dose 70 mg/day, subsequent 50 mg/day) and
voriconazol (400 mg/day). Resource use data and costs were
obtained from hospital records from one tertiary care hospital at
IMSS (n = 25). The model was calibrated according to interna-
tional pharmacoeconomics guidelines. One-way and probabilis-
tic sensitivity analyses were performed using Monte Carlo
Simulation second-order approach. RESULTS: Patients who
received anidulafungin experienced 58.8%(CI95%51.0%–
65.5%) of clinical success without AE, followed by limposomal
amphotericin B (46.7%[CI95%35.9%–61.6%]) and ﬂuconazol
(45%[CI95%37.8%–51.8%]). Patients treated with anidulafun-
gin were hospitalized with a mean of 15.4(CI95%8.5–22.2)
days in ICU followed by limposomal amphotericin B
(17.2[CI95%10.0–23.6]) and ﬂuconazol (17.5[CI95%10.8–
24.1]). Mean cost per patient were lower with anidulafungin
(US$32,711[CI95%US$29,720–US$36,456) followed by
limposomal amphotericin B (US$35,713[CI95%US$31,628–
US$39,660]) and ﬂuconazol (US$36,688[CI95%US$33,501–
US$40,402]). Based on ICERs, anidulafungin was the dominant
therapy. Acceptability curves and component analyses showed
anidulafungin as the most cost-effective therapy in a range of
80%–90% (p < 0.05). CONCLUSION: In Mexico, anidulafun-
gin was the most cost-effective antifungal therapy for invasive
candidiasis. These results should be taken into account by
Mexican decision makers in the management of non neutropenic
patients with invasive candidiasis.
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OBJECTIVE: Invasive candidiasis is a serious infectious disease
with high incidence and important economic impact due to its
long hospitalizations. The purpose of this study was to estimate
the cost-effectiveness of anidulafungin and other antifungal
agents in the management of invasive candidiasis in non-
neutropenic patients from the payer’s perspective. METHODS:
A Bayesian decision tree model allowing switches among differ-
ent antifungal treatments was performed. The model simulates
costs and effectiveness in a 12-week-period. Effectiveness mea-
sures were the rate of clinical success and percentage of survival.
Clinical efﬁcacy and transition probabilities were obtained from
published literature. Comparators were anidulafungin (100 mg/
day), amphotericin B (0.6 mg/kg/day) and ﬂuconazol (initial dose
400 mg/day, subsequent 200 mg/day). Resource use data and
costs were obtained from a tertiary care hospital “Hospital de
Especialidades” CMN Siglo XXI from the Social Security
Mexican Institute (n = 25). Resource use include: inpatient ser-
vices, intensive care unit, drugs and surgery. One-way sensitivity
analysis was performed and other probabilistic sensitivity
analyses were constructed. RESULTS: Patients treated with
anidulafungin experienced the higher clinical success (74.02%)
followed by amphotericin B (63.51%) and ﬂuconazol (56.78%).
On the other hand, anidulafungin yielded 77.17% of total-
survival followed by ﬂuconazol with 68.64% and amphotericin
B with 62.19%. The mean total costs per patient were
US$47,993 for anidulafungin; US$59,350 for ﬂuconazol and
US$60,349 for amphotericin B. ICERs estimated using amphot-
ericin B as the baseline strategy using clinical success as effec-
tiveness outcome were -US$117,633 for anidulafungin and
US$14,847 for ﬂuconazol. ICER’s estimated using the same com-
parator for total-survival as effectiveness was -US$82,503 for
anidulafungin and -US$15,482 for ﬂuconazol. Sensitivity analy-
ses showed that anidulafungin was the dominant strategy
(p < 0.05). CONCLUSION: In Mexico, anidulafungin treatment
was a cost-saving therapy not only because of its higher clinical
success and survival but for its potential cost reduction. These
results should be considered by Mexican decision-makers in
future cost-containment policies.
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